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Human minor histocompatibility antigens 
EIs Goulmy 
Disparities in minor histocompatibility antigens between 
HLA-matched organ and bone marrow donors and 
recipients create a potential risk for graft failure and 
graft-versus-host disease. These conditions necessitate 
lifelong pharmacological immunosuppression of organ and 
bone marrow transplant recipients. Recent technical advances 
have resulted in the identification of the chemical nature of 
the first human minor histocompatibility antigens. A new era 
of research has begun to provide insights into the genetics of 
minor antigens and their putative role in transplantation. 
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Abbreviations 
BMT bone marrow transplantation 
CTL cytotoxic T lymphocyte 
GVHD graft-versus-host disease 
LCL lymphoblastoid cell line 
mHeg minor histocompatibility antigen 
TH T helper 
In t roduct ion  
Minor histocompatibility antigens (mHag) have been re- 
ported to account for complex events resulting from organ 
and tissue exchange between MHC identical individuals. 
The classical definition of mHag dates from 1948 and 
originates from studies by Snell [1], who described genetic 
loci responsible for tumor graft rejection. In contrast o 
major antigens, mHags account for a comparatively slower 
and more chronic graft rejection [21. Not having access 
to the experimental possibilities afforded by inbred and 
congenic strains, we will never be able to verify the latter 
statement in man. Yet, in man, simultaneously with the 
matching for the HLA antigens to improve the success of 
ailogeneic bone marrow transplantation [3], non-HLA (i.e. 
mHag) became vident. 
The possible involvement of mHags in human trans- 
plantation was first reported two decades ago [4]. It 
dealt with a clinical observation in a female patient 
who received, after ATG pre-treatment, the bone marrow 
of a male HLA-identical sibling. In vitro analysis of 
the post-transplant peripheral blood lymphocytes of the 
female patient showed unambiguously that there were 
strong cytotoxic T lymphocyte (CTL) responses that were 
specific for the male donor HLA-matched target cells 
[4,5]. Since this observation, we and others have also 
described the recognition of human mHags under similar 
circumstances [6]. 
Until recently, human mHags were defined by in vitro 
studies of the T-cell reactivity of cells derived from 
individuals primed in vivo. The ability of T cells to mount 
a response specific for mHags can be described as 'peptide 
alloreactivity' (i.e. MHC-restricted T cells react with 
immunogenic peptides). The situation arises between 
HLA-identical individuals when a mHag is present in 
one individual, but absent from the other. Isolation and 
characterization of the human mHag peptides that are 
reactive in allograft situations has now begun. It is 
therefore timely to study the genetics and immunogenic 
potential of human mHags. This review summarizes the 
recent advances in human mHag immunobiology and 
discusses these data in relation to its relative clinical 
importance. 
T-cel l  de f ined  human mHags :  genet ics  and  
po lymorph ism 
mHags have been defined by MHC-restricted T cells 
obtained from individuals primed in vivo through organ 
or bone marrow grafting and blood transfusions [6]. Series 
of mHag-specific MHC class I-restricted CTL  populations 
and MHC class II-restricted T-helper (Th) cells have been 
described [6,7]. Yet, little information is currently available 
about population frequencies, segregation patterns and 
allelism of mHags. From the data gathered so far 
(see Tables 1 and 2), one may conclude that mHag 
are recognized in the context of class I and class II 
alleles, that the majority of T-cell defined mHags are 
determined by autosomai genes inherited in a Mendelian 
fashion and that they show either high or low phenotype 
frequencies. From genetic analysis of our CTL-defined 
HLA-A2.1-restricted mHag, HA-I, HA-2, HA-4 and HA-5, 
it was clear that these four antigens can each be considered 
the product of a gene with one allele expressing the 
detected specificity, and one or more alleles not expressing 
it. Although our family data did not provide sufficient 
information concerning linkage between the different mH 
loci themselves and HLA, all of our tests were compatible 
with the hypothesis that these loci are independent ofeach 
other and independent of HLA [8]. 
Unlike the genes encoding mHags in the mouse (as re- 
viewed in [9]), the human genes encoding mHags - -  with 
the exception of the gene encoding the male-specific 
mHag H-Y (see below) - -  have not yet been identified. It 
is not yet known how many alleles exist for each locus, 
nor what the total number of mH loci is. In view of what 
is known about murine mHags, however, [10,11] a few 
allelic forms may exist for each locus. The supposedly 
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low polymorphism ay result from the presentation of 
homologous, but not identical, peptides from the same 
protein, or failure to present a peptide because it lost an 
(anchor) amino acid residue. Alternatively, polymorphism 
in the antigen-processing systems may result in a failure 
to express the peptide. 
Table 1 
Cellularly defined daes I-restricted mHag. 
Restriction Code Population Mode of Reference 
molecules (local) frequency segregation 
A1 HA-3 880/o Mendalian¢ [23] 
A1 H-Y Males Y-linked [65] 
A2.1 H-Y Males Y-linked [4] 
A2.1 HA-1 69% Mendalian [23] 
A2.1 HA-2 95% Mendalian [23] 
A2.1 HA-4 16% Mendalian [23] 
A2.1 HA-5 7% Mendalian [23] 
B7 Wl  1101141 * Mendalian [66] 
B7 H-Y Males Y-linked [67] 
B7 HA-6 15116 NT 
B7 HA-7 13/15 NT 
B7/B27/B40 - 719 NT [68] 
B35 NH5.2t 23•23 Mendalian [69] 
B38 NH54 314 Mendalian [7(3] 
B44 Sol 29151 Mendalian [71] 
B60 H-Y Males Y-linked [72] 
*Number of individuals/total number of individuals tested, tMore clones 
with identical specificity. $Mendalian indicates family studies performed. 
In case of [23], Mendalian traits of inheritance were demonstrated. NT, 
not tested. 
Immunodominant mHag: are there major 
minors? 
mHags are naturally processed peptide fragments orig- 
inating from intracellular proteins that associate with 
MHC products. This implies the potential existence of 
a large number of mHags. The fact that a significant 
number of bone marrow transplants between HLA-iden- 
tical sibling (with optimal immunosuppression) do not 
lead to graft-versus-host disease (GVHD) [12], suggests 
a hierarchy in immunogenicity. Indeed, in vitro studies 
have detected multiple differences in the mHags between 
HLA-identical recipient/bone marrow donor combinations 
[13]. Yet, probably only a limited number of these mHags 
exhibits immunizing potential, as exemplified by our 
recent study where we observed a significant correlation 
between mismatch for one mHag (HA-l) and GVHD in 
adult patients [14°°]. Multiple factors will determine the 
immunogenic potential of a mHag to activate aT cell. The 
synergistic effects of mH-specific Th -CTL  collaboration, 
as has been reported for murine mHag [15], may be one 
such factor. 
Table 2 
Cellularly defined daes II-restricted mHag. 
Restriction Code Population Mode of Reference 
molecules (local) frequency segregation 
DR2/DR3 LG2 13•20 Mendaliant [23] 
DR2 PN2 17% Mendalian [23] 
DR2 ID10 10•25 Mendalian [73] 
DR3 H-Y Males Y-linked [73] 
DR5 Bur-1 40o/0 Mendalian [74] 
DRw6/DRwl0 LH3 11124 NT [23] 
DR9 A2* 5•20 NT [75] 
DP4 LG29 NT Mendalian [a] 
DR2 11 NT NT [76] 
DR/DP/DQ - NT NT [77] 
[a] E Goulmy, unpublished data. *More clones were obtained with 
identical specificity, tMendalian indicates that family studies were 
performed. In [23], Mendalian traits of inheritance were demonstrated. 
NT, not tested. 
peptide [16 °°] classified this peptide among the highest 
affinity naturally processed peptides that have been 
identified to date. The concentration of the HA-2 peptide 
as competitor peptide that resulted in 50% inhibition of 
the iodinated peptide binding (IC50) was 6.7 nM. IC50% 
values for other peptides vary from l l -214nM [17,18]. 
The sequence of HA-2 included amino acids at positions 
4 and 9 that had previously been characterized as strong 
anchor residues for HLA-A2.1 [19]. The presence of 
isoleucine at position 2, known to fit the HLA-A2.1 motif, 
but not recognized as a frequent anchor residue, is of 
interest. The affinity of MHC class I-peptide binding is 
crucial for the outcome of an immune response, even in 
the situation of subdominant epitopes [20°]. Nevertheless, 
as pointed out by Barber and Parham [21], a number of 
factors other than peptide MHC affinity determine the 
successful outcome of an immune response. 
Hierarchy in immunodominance amongst mHags may be 
reflected in a skewed T-cell repertoire usage for mHag- 
specific responses. In our study, we observed a limited 
TCR VI] region usage, as well as remarkable similarities 
within the N-D-N regions among mHag HA-l-specific 
CTL  clones derived from unrelated individuals [22°]. 
Moreover, CTL  clones reactive for the same mHags 
HA-1 were obtained from peripheral blood lymphocytes 
of three out of five individuals, each transplanted across 
a barrier of multiple and probably distinct mH [23]. In 
this regard, the most challenging observations are those 
of the in vivo expansion of T-cell subsets with selective 
TCR usage during acute GVHD after HLA-identicai bone 
marrow transplantation [24°]. An anti-host T-cell clone 
with defined TCR VI~ usage was shown to persist in a 
chronic GVHD patient up until a year after HLA-identical 
The peptide affinity for the MHC molecules could bone marrow transplantation [25°]. These observations 
also influence the immunological outcome, Using an " reveal that the mHag-specific TCR repertoire seems to be 
equilibrium binding assay to measure relative affinities, limited. Therefore the response must be directed toward 
binding sites of the recently identified mHag HA-2 only a few or a single mHag. 
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The production of cytokines is crucial for the induction of 
mHag effector cells. Without doubt, cytokines do play a 
significant role in the development of GVHD (for reviews 
see [26-28]). The inflammatory cytokines IL-113, IL-6 
and tumor necrosis factor (TNF)-ct seemed to play an 
important role in the development of GVHD [29,30]. In 
a murine model, IL-lct has been postulated as a critical 
effector molecule in mHag-directed GVHD [31]. To my 
knowledge, no information exists about the contribution 
of cytokines to the activation of human mHag-specific 
effector cells in organ or bone marrow grafting. 
Naturally, the impact of mHags on the outcome of organ 
and bone marrow grafting is dependent on, amongst other 
factors, their tissue distribution. Table 3 summarizes the 
tissues and cells we have studied to date. We have 
observed either ubiquitous or restricted tissue distribu- 
tion of the mHags analysed (see Table 3 for details). 
Expression of the non-sex-linked mHags (i.e. HA-I, HA-2 
and HA-5) [32], is restricted to the haematopoietic-cell 
lineage, including epidermal-derived Langerhans cells 
[33], whereas H-Y, HA-3 and HA-4 were found to be 
expressed on cells of all tissues tested, including cord 
endothelial cells and kidney proximal tubular epithelial 
cells [32]. Additional experiments from our laboratory 
showed functional expression of H-Y and HA-3 on corneal 
scleral tissue as well [34]. Broad tissue distribution has also 
been demonstrated by other investigators. Recognition of 
mHag on phytohemagglutinin (PHA) blasts, lymphoblas- 
told cell lines (LCLs) and keratinocytes was described 
by Niederwieser et al. [35] and the expression of an 
HLA-B35-restricted mHag on cultured kidney cells was 
demonstrated by Beck et aL [36]. 
Of special interest are tissue-specific antigens described by 
Yard et al. [37] and Poindexter et aL [38*]. Both groups 
reported the isolation of graft-infiltrating T lymphocytes 
during cellular rejection, and have shown MHC class 
I-restricted lysis of kidney cells, but not of PHA blasts or 
LCLs. Moreover, kidney-specific polymorphism ay exist 
[39]. Recently, an HLA-A3-restricted, kidney-specific, 
T-cell epitope was successfully isolated and sequenced; 
however, the origin of the protein is, as yet, uncharacter- 
ized [40°°]. 
Cl in ica l  re levance  
Most of the clinically related studies of mHags have 
concerned bone marrow grafting. As mentioned above, 
although derived from MHC mismatched onor/recipient 
combinations, the data on kidney tissue specific CTL  
clones are valuable in the understanding of the pathology 
of renal allograft rejection. 
Several reports have described the presence of CTLs 
specific for anti-host mHag in patients suffering from 
GVHD after HLA genotypically identical BMT (reviewed 
in [41]). We investigated the influence of mHag H-Y and 
HA-I-HA-5 mismatches on the development of GVHD 
Table 3 
Tissue distribution of human minor histocompaUbilty 
antigens H-Y and HA-1 to HA-5. 
Cell type HA-1 HA-2 HA-3 H-Y HA-4 HA-5 
Haematopoietic progenitor + + + + + + 
cells 
Clonogenic leukemia + + + + + + 
precursor cells* 
Thymocytes + + NT + NT NT 
PBLs + + + + + + 
PBL blasts + + + + + + 
EBV BLCL + + + + + + 
Monocytes + + + + + + 
Dendritic cells + + + + + + 
Langerhans cells (skin) + + + + + NT 
Leukaemic cellst 
myeloid + + + + + + 
lymphocytic + + + + + + 
Fibroblasts + + + 
Keratinocytes + + + 
Melanocytes + + 
Melanomas + + + 
Cord endothelial cells + + 
Kidney proximal tubular + + 
epithelial cells 
*[47]. t[48]. Remaining data derived from [29] and [30]. PBLs, 
peripheral blood lymphocytes; EBV BLCL, Epstein-Barr virus B 
lymphoblastoid cell line; NT, not tested. 
after bone marrow transplantation from HLA-identical 
donors. In a retrospective study of 148 HLA genotypically 
identical bone marrow donor-recipient pairs, we observed 
a significant correlation between mHag HA-1 mismatch 
and the development of GVHD in adult patients. Thus, 
prospective HA-1 typing would improve donor selection 
and identify recipients who are at high risk for GVHD 
[14°°]. 
Over the past few years, evidence has accumulated to 
suggest hat, in addition to CTLs, mHag-specific Th cells 
could be relevant o the pathogenesis of GVHD. In vitro 
studies have reported on host-directed Th cells in patients 
with GVHD (as reviewed in [41]). Th-cell responses to 
host mHag measured either the 'bulk' level [42] or at the 
Th-cell precursor level [43] correlate with GVHD. Analysis 
of putative mHag-specific Th-cell precursor frequencies 
before HLA-identical bone marrow transplantation proved 
to be valuable [44,45]. In a subsequent s udy, it was shown 
that both CD4+ and CD8 ÷ T-cell subsets participated in 
the pre-transplant anti-host responses [46]. 
Another area of possible involvement of mHag is the so 
called graft-versus-leukemia (GVL) effect that, according 
to clinical data, parallels acute and chronic GVHD. The 
supposition that donor-derived mHag-specific T cells may 
be involved in the eradication of residual leukemic ells is 
attractive. One line of investigation supporting this notion 
is that mHag-specific CTLs are capable of inhibiting in 
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vitro outgrowth of clonogenic leukemic precursor cells 
[35,47], as well as lysing freshly obtained myeloid and 
lymphoid leukemic ells [35,48]. 
Besides donor-derived T cells reactive for ligands (like 
mHags) that are shared by host PBLs and leukemic 
cells, anti-host CTL  responses with anti-leukemic activity 
in vitro can also be observed on either PHA blasts or 
leukemic cells [49-51]. This is to say that some experts 
argue that GVH and GVL are caused by different T-cell 
populations, whereas non-separable ffector cells that 
exhibit both activities, also exist [49]. Additional detailed 
clinical and laboratory studies are really needed in this 
exciting and complicated area of clinically-related research. 
We also need to explain the exceptions to the rule: 'no 
GVHD/no relapse' and 'GVHD/relapse'. 
Isolation and characterization of human 
mHags 
In 1948, Snell [1] reported "the existence of rare h genes 
coded for by separate histocompatibility loci. Is there any 
way that these loci can be discovered? There is no simple 
method of finding them but that by the use of somewhat 
laborious methods they can eventually be brought to 
light". 
Snell was right, mH genes can be identified, although 
the methodology is cumbersome. Two main lines of 
investigation have led to the definition of the limited 
number of mH peptides that are known to date. The 
first strategy involves the enormous task of sequencing 
stretches of genomic DNA known to include the genes 
encoding the mH T-cell epitope. Subsequent cellular 
testing of synthetic peptides generated according to the 
deduced protein sequences has resulted in the definition 
of peptides recognized by mH antigen-specific T-cell 
clones [52]. Using this approach, CTL  clones defining 
Mta, a maternally transmitted mitochondrial murine mH 
antigen, were found to recognize synthetic peptides 
corresponding to a polymorhpic part of mitochondrial 
ND-1 [53]. Hydrophobic peptides of 17-26 amino acids in 
length were efficiently recognized, peptides of 12 amino 
acids were moderately well recognized, whereas shorter 
stretches did not sensitize target cells for recognition by 
anti-Mta CTLs at all. 
Demotz et al. [54] were the first to isolate and characterize 
naturally processed peptides from MHC molecules. Ram- 
mensee and his colleagues successfully applied immunop- 
urification and biochemical isolation techniques to extract 
routine mH peptides from class I molecules. As was true 
for other T-cell recognized antigens, such as viral [55] and 
non-viral proteins [54], they found that the murine mHags 
H-Y and H-4 were naturally processed proteins, probably 
of a peptidic nature [56,57]. 
Sekimata et al. [58] and De Bueger et al. [59] managed to 
isolate fractions containing mHag peptides, but failed to 
obtain the actual amino-acid sequence from the peptide 
pool eluted from MHC class I molecules. Thanks to the 
technical advances of Hunt et al. [60], the application 
of a microcapillary HPLC-electrospray ionization tandem 
mass spectrometry enabled the detection of non-abundant 
peptides among a pool of MHC-bound peptides. Our joint 
forces allowed the first identification of two classical mHag: 
the human mHag HA-2 and the male-specific mHag H-Y 
[16"',61"]. The HA-2 peptide most probably originates 
from a member of the non-filament-forming class I myosin 
family, a large family of proteins that are involved in cell 
locomotion and organelle transport [621. The H-Y antigen 
presented by HLA-B7 is an l 1-residue peptide derived 
from SMCY, an evolutionarily conserved protein encoded 
by the Y chromosome [63"']. Besides the role of H-Y as 
a transplantation a tigen, the human Y gene controlling 
the expression of the HLA-B7-restricted mHag H-Y T-cell 
epitope is possibly also functioning as a gene controlling 
spermatogenesis [64]. Concurrent with the identification 
of the human H-Y peptide, a murine H-Y peptide was 
characterized and appeared to be derived from the same 
evolutionarily conserved SMCY protein [63"']. 
Besides the identification of other class I-restricted human 
mHag peptides, we are currently aiming at characterizing 
the biochemical nature of MHC class II-restricted human 
mHags. In view of the limited information on their 
genetics and polymorphisms, it is of particular interest o 
find out whether the class II mHags belong to the small 
number of cytosolic proteins that have deviated to the 
endosomal processing pathway. 
Conclusions 
Significant information has been gathered over the past 
few years on human mHags. Although the number of mH 
systems is expected to be large, probably only a limited 
number will fulfil the necessary criteria (i.e. frequency, 
immunogenicity and tissue distribution) for being a risk 
factor for GVHD or rejection. Dissection of the major 
from the minor minors and their biochemical identification 
may aid in immunomodulatory approaches. The potential 
applications vary from tolerance induction in organ and 
bone marrow grafting, to the design of prophylaxis against 
GVHD and rejection. Most promising is immunotherapy 
using CTLs specific for mHag peptide for the treatment 
of residual, refractory or relapsed leukemia. Finally and 
less far-fetched, as more mHags become biochemically 
identified, their use for diagnostic in bone marrow donor 
selection by molecular typing. 
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